Novel Imaging Markers in SPMS
Novel Imaging Markers of Innate Immune Activation in Secondary Progressive Multiple Sclerosis
We could not find results for this trial
What it found
We found no results in the registry or in papers.
This trial finished 3 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Ferumoxytol
Unknown
- MRI Brain and Cervical Spine
Given for the study's measurements
- Gadoteridol
Diagnostic agent
What it measured
Main measures
Signal change on T1-weighted and 3D UTE MRI brain (and upper cervical cord) before and 96 hours (±24 hours) after ferumoxytol administration
96 hours ±24 hours
MRI lesions
Other measures (1)
Incidence of treatment-emergent adverse events (safety and tolerability)
96 hours ±24 hours
Safety
Who could take part
Progressive MS · 35 to 65
Show the full criteria
Inclusion criteria
1. Adults age 35 to 65 years 2. Clinically diagnosed with secondary progressive multiple sclerosis (SPMS) (2017 McDonald Criteria) 3. Worsening 25 foot walk time (worsening SPMS cohort) over the preceding 2 years. 4. Ambulatory with ability to walk at least 20 meters without rest, with or without aid 5. Ability and willingness to attend study visits and complete the study
Exclusion criteria
1. Clinically diagnosed with relapsing remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), clinical isolated syndrome (CIS), or radiologically isolated syndrome (RIS) 2. Clinical MS relapse and/or new MRI lesion(s) within the preceding 2 years 3. Positive pregnancy test 4. Gadolinium contrast allergy 5. Acute or chronic kidney disease with eGFR \<30 ml/min/1.73m2 6. Pacemaker or other MRI contraindications per American College of Radiology guidelines 7. Intravenous iron sensitivity 8. Serum ferritin and transferrin saturation above age-adjusted upper limit of normal (if serum ferritin is above normal, but transferrin saturation is normal, the subject is NOT excluded)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinning neurologic worsening in progressive MS. As such, in the short term this project proposes to investigate USPIO uptake in SPMS lesions as a promising in vivo imaging biomarker for chronic-active lesions, as distinguished from chronic-inactive lesions.
Papers
Loading reviews and guidelines…
Related trials
- Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predictin
Completed
Results posted, not judged
- Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel
Not a drug-phase study · Status unknown
No results found
- Imaging of inflammation in the cortex of the brain in progressive MS p
Phase 2 · Completed
No results found
History
Started
Jun 2022
Main results due
Sept 2023
Finished
Sept 2023